|Videos|February 24, 2023
Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice
Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.
Advertisement
Episodes in this series
January 2023 AbbVie Inc. Company Confidential
Advertisement
Related to this article
The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Why Caregivers Are Critical During Bispecific Step-Up Dosing
4
Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL
5